<DOC>
	<DOCNO>NCT01922661</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability single ascending dos subcutaneously ( SC ) administer REGN1908-1909 allergic , adult subject .</brief_summary>
	<brief_title>Single Ascending-dose Study Safety , Tolerability , Pharmacokinetics REGN1908-1909 Allergic , Adult Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy men woman age 18 55 2 . Positive allergen skin prick test 3 . Willing able comply clinic visit studyrelated procedure 4 . Provide sign informed consent 1 . Persistent , chronic , active recur infection require treatment antibiotic , antiviral , antifungal within 4 week prior screen visit 2 . Any clinically significant ( determined investigator 's discretion ) abnormalities observed screen physical examination 3 . Onset new exercise routine major change previous exercise routine within 4 week prior screen visit . Patients must willing maintain similar level exercise duration study refrain unusually strenuous exercise duration trial 4 . Hospitalization reason within 60 day prior screen visit 5 . Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives ( whichever longer ) investigational drug prior screen visit 6 . Any medical psychiatric condition opinion investigator Regeneron , would place patient risk , interfere participation study interfere interpretation study result The information list intend contain consideration relevant patient 's potential participation clinical trial inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>